Learning Objectives:

  • Review tyrosine kinase inhibitors in the management of sensitizing epidermal growth factor receptor (EGFR) mutant NSCLC
  • Discuss mechanisms of resistant to osimertinib therapy, and clinical trial options at time of progression
  • Present treatment options for uncommon EGFR mutations
  • Address the role of immunotherapy in the treatment of EGFR+ NSCLC
Session date: 
12/02/2019 - 12:00pm to 1:00pm CST
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or create an account to proceed.
Speaker Name: 
Christine Bestvina